Gue 1654CAS# 397290-30-1 |
- Salmefamol
Catalog No.:BCC1919
CAS No.:18910-65-1
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 397290-30-1 | SDF | Download SDF |
PubChem ID | 5066134 | Appearance | Powder |
Formula | C23H17N3OS3 | M.Wt | 447.6 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in DMSO | ||
Chemical Name | N-(2-methylsulfanyl-[1,3]thiazolo[4,5-g][1,3]benzothiazol-7-yl)-2,2-diphenylacetamide | ||
SMILES | CSC1=NC2=C(S1)C3=C(C=C2)N=C(S3)NC(=O)C(C4=CC=CC=C4)C5=CC=CC=C5 | ||
Standard InChIKey | UFOBDFMYJABXGK-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H17N3OS3/c1-28-23-25-17-13-12-16-19(20(17)30-23)29-22(24-16)26-21(27)18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-13,18H,1H3,(H,24,26,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Oxoeicosanoid receptor 1 (OXE-R) modulator. Selectively inhibits Gβγ but not Gαi signaling upon activation of the Gαi-βγ heterotrimer by OXE-R. Inhibits Gβγ-mediated opening of GIRK1/2 channels in HEK293 cells. |
Gue 1654 Dilution Calculator
Gue 1654 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2341 mL | 11.1707 mL | 22.3414 mL | 44.6828 mL | 55.8534 mL |
5 mM | 0.4468 mL | 2.2341 mL | 4.4683 mL | 8.9366 mL | 11.1707 mL |
10 mM | 0.2234 mL | 1.1171 mL | 2.2341 mL | 4.4683 mL | 5.5853 mL |
50 mM | 0.0447 mL | 0.2234 mL | 0.4468 mL | 0.8937 mL | 1.1171 mL |
100 mM | 0.0223 mL | 0.1117 mL | 0.2234 mL | 0.4468 mL | 0.5585 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Daphmacropodine
Catalog No.:BCN5450
CAS No.:39729-21-0
- Catharticin
Catalog No.:BCN6850
CAS No.:39723-40-5
- 2-Benzylsuccinic acid
Catalog No.:BCC8566
CAS No.:3972-36-9
- 1,5-Diphenylpentan-1-one
Catalog No.:BCN7169
CAS No.:39686-51-6
- (R)-Reticuline
Catalog No.:BCN6795
CAS No.:3968-19-2
- BVT 948
Catalog No.:BCC2467
CAS No.:39674-97-0
- Azatadine
Catalog No.:BCC4133
CAS No.:3964-81-6
- Isoshinanolone
Catalog No.:BCN7986
CAS No.:39626-91-0
- LY364947
Catalog No.:BCC5085
CAS No.:396129-53-6
- Pasireotide
Catalog No.:BCC5300
CAS No.:396091-73-9
- Z-Sar-OH
Catalog No.:BCC3339
CAS No.:39608-31-6
- Triamterene
Catalog No.:BCC5074
CAS No.:396-01-0
- SDZ 21009
Catalog No.:BCC7098
CAS No.:39731-05-0
- H-Gln-OtBu.HCl
Catalog No.:BCC2918
CAS No.:39741-62-3
- 16,16-Dimethyl Prostaglandin E2
Catalog No.:BCC7843
CAS No.:39746-25-3
- Dehydrovomifoliol
Catalog No.:BCN7562
CAS No.:39763-33-2
- Bryonolol
Catalog No.:BCN2703
CAS No.:39765-50-9
- 2-Amino-4-hydroxy-6-methylpyrimidine
Catalog No.:BCC8531
CAS No.:3977-29-5
- Boc-Tyr-OH
Catalog No.:BCC3458
CAS No.:3978-80-1
- Azatadine dimaleate
Catalog No.:BCC4536
CAS No.:3978-86-7
- Penciclovir
Catalog No.:BCC4695
CAS No.:39809-25-1
- Taibaihenryiins A
Catalog No.:BCN3281
CAS No.:398129-59-4
- Epitulipinolide diepoxide
Catalog No.:BCN5451
CAS No.:39815-40-2
- H-Ala-OiPr.HCl
Catalog No.:BCC3193
CAS No.:39825-33-7
A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer.[Pubmed:22634634]
Nat Chem Biol. 2012 Jul;8(7):631-8.
Differential targeting of heterotrimeric G protein versus beta-arrestin signaling are emerging concepts in G protein-coupled receptor (GPCR) research and drug discovery, and biased engagement by GPCR ligands of either beta-arrestin or G protein pathways has been disclosed. Herein we report on a new mechanism of ligand bias to titrate the signaling specificity of a cell-surface GPCR. Using a combination of biomolecular and virtual screening, we identified the small-molecule modulator Gue1654, which inhibits Gbetagamma but not Galpha signaling triggered upon activation of Galpha(i)-betagamma by the chemoattractant receptor OXE-R in both recombinant and human primary cells. Gue1654 does not interfere nonspecifically with signaling directly at or downstream of Gbetagamma. This hitherto unappreciated mechanism of ligand bias at a GPCR highlights both a new paradigm for functional selectivity and a potentially new strategy to develop pathway-specific therapeutics.